Caroline Elisabeth Nunes-Xavier
- Principal investigator; PhD
- +47 22 78 18 75
Dr. Nunes-Xavier is an experimental biologist and cancer researcher that initiated her career at the University of Oslo, where she obtained a Bachelor Degree in Natural Sciences (2005) and a Master Degree in Molecular Biology (2006). During the Master Degree, she made a mobility stay, within the Erasmus program, to the University of Valencia (Spain), where she obtained an additional Master Degree in Molecular Biology (2007). Afterwards she was awarded with a Marie Skłodowska-Curie Fellowship to perform her PhD (2007-2011), as part of a European Research Network training program, and obtained her European PhD at the University of Valencia (Spain) in 2011. During her PhD period she performed secondments at Karolinska Institute in Sweden and Weizmann Institute in Israel. Dr. Nunes-Xavier started as a postdoc at Oslo University Hospital in 2013 with a fellowship from the Norwegian Cancer Society. Since 2015 Dr. Nunes-Xavier has been a Principal Investigator and a holder of a FRIPRO mobility grant from The Research Council of Norway, co-funded by Marie Skłodowska-Curie Actions.
Dr. Nunes-Xavier main research line is to define novel targets in cancer treatment, with a focus on immune checkpoint proteins and protein tyrosine phosphatases. The pursued goals will have an important clinical translation to overcome or prevent cancer disease progression and current resistance to therapy.
Publications 2024
Predicting Survival of Metastatic Clear Cell Renal Cell Cancer Treated with VEGFR-TKI-Based Sequential Therapy
Cancers (Basel), 16 (16)
DOI 10.3390/cancers16162786, PubMed 39199559
A functional role for glycosylated B7-H5/VISTA immune checkpoint protein in metastatic clear cell renal cell carcinoma
iScience, 27 (9), 110587
DOI 10.1016/j.isci.2024.110587, PubMed 39262813
Editorial: Co-inhibitory immune checkpoint proteins as biomarkers and therapeutic targets in cancer
Transl Oncol, 47, 102005
DOI 10.1016/j.tranon.2024.102005, PubMed 39034056
B7-H3: a robust target for immunotherapy in prostate cancer
Trends Cancer, 10 (7), 584-587
DOI 10.1016/j.trecan.2024.05.003, PubMed 38839545
Induction of Translational Readthrough on Protein Tyrosine Phosphatases Targeted by Premature Termination Codon Mutations in Human Disease
Methods Mol Biol, 2743, 1-19
DOI 10.1007/978-1-0716-3569-8_1, PubMed 38147205
Potentiation by Protein Synthesis Inducers of Translational Readthrough of Pathogenic Premature Termination Codons in PTEN Isoforms
Cancers (Basel), 16 (16)
DOI 10.3390/cancers16162836, PubMed 39199607
Publications 2023
Distinct spatial landscapes in clear-cell renal cell carcinoma as revealed by whole transcriptome analysis
Immunooncol Technol, 21, 100690
DOI 10.1016/j.iotech.2023.100690, PubMed 38292905
The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma
Sci Rep, 13 (1), 7339
DOI 10.1038/s41598-023-34087-x, PubMed 37147361
Author Correction: The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma
Sci Rep, 13 (1), 9186
DOI 10.1038/s41598-023-36328-5, PubMed 37280349
Editorial: Cell and Developmental Signalling in Neuroblastoma
Front Cell Dev Biol, 10, 1126352
DOI 10.3389/fcell.2022.1126352, PubMed 36684434
Novel anti-PTEN C2 domain monoclonal antibodies to analyse the expression and function of PTEN isoform variants
PLoS One, 18 (8), e0289369
DOI 10.1371/journal.pone.0289369, PubMed 37527256
Publications 2022
Identification and Functional Analysis of a Novel CTNNB1 Mutation in Pediatric Medulloblastoma
Cancers (Basel), 14 (2)
DOI 10.3390/cancers14020421, PubMed 35053583
B7-H4 Immune Checkpoint Protein Affects Viability and Targeted Therapy of Renal Cancer Cells
Cells, 11 (9)
DOI 10.3390/cells11091448, PubMed 35563753
Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer
Pathol Res Pract, 241, 154243
DOI 10.1016/j.prp.2022.154243, PubMed 36481650
Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer
Front Oncol, 12, 873516
DOI 10.3389/fonc.2022.873516, PubMed 35692804
Hopes on immunotherapy targeting B7-H3 in neuroblastoma
Transl Oncol, 27, 101580
DOI 10.1016/j.tranon.2022.101580, PubMed 36327699
Functional analysis of PTEN variants of unknown significance from PHTS patients unveils complex patterns of PTEN biological activity in disease
Eur J Hum Genet, 31 (5), 568-577
DOI 10.1038/s41431-022-01265-w, PubMed 36543932
Publications 2021
(Pro)renin Receptor Is a Novel Independent Prognostic Marker in Invasive Urothelial Carcinoma of the Bladder
Cancers (Basel), 13 (22)
DOI 10.3390/cancers13225642, PubMed 34830803
A global analysis of the reconstitution of PTEN function by translational readthrough of PTEN pathogenic premature termination codons
Hum Mutat, 42 (5), 551-566
DOI 10.1002/humu.24186, PubMed 33600059
Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer
Prostate, 81 (12), 838-848
DOI 10.1002/pros.24180, PubMed 34125445
Protein Tyrosine Phosphatases in Neuroblastoma: Emerging Roles as Biomarkers and Therapeutic Targets
Front Cell Dev Biol, 9, 811297
DOI 10.3389/fcell.2021.811297, PubMed 34957126
MMADHC premature termination codons in the pathogenesis of cobalamin D disorder: Potential of translational readthrough reconstitution
Mol Genet Metab Rep, 26, 100710
DOI 10.1016/j.ymgmr.2021.100710, PubMed 33552904
Publications 2020
Brain Circuit Alterations and Cognitive Disability in Late-Onset Cobalamin D Disorder
J Clin Med, 9 (4)
DOI 10.3390/jcm9040990, PubMed 32252256
B7-H3 Immune Checkpoint Protein in Human Cancer
Curr Med Chem, 27 (24), 4062-4086
DOI 10.2174/0929867326666190517115515, PubMed 31099317
Publications 2019
The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder
Hum Pathol, 91, 61-68
DOI 10.1016/j.humpath.2019.07.002, PubMed 31279874
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
Sci Rep, 9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582
Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology
NPJ Precis Oncol, 3, 11
DOI 10.1038/s41698-019-0083-4, PubMed 30993208
A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma
Curr Urol Rep, 20 (1), 1
DOI 10.1007/s11934-019-0866-8, PubMed 30645700
Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma
Diagn Pathol, 14 (1), 134
DOI 10.1186/s13000-019-0919-9, PubMed 31837707
Dual-Specificity Phosphatases in Neuroblastoma Cell Growth and Differentiation
Int J Mol Sci, 20 (5)
DOI 10.3390/ijms20051170, PubMed 30866462
Precise Immunodetection of PTEN Protein in Human Neoplasia
Cold Spring Harb Perspect Med, 9 (12)
DOI 10.1101/cshperspect.a036293, PubMed 31501265
Publications 2018
DUSP5 expression associates with poor prognosis in human neuroblastoma
Exp Mol Pathol, 105 (3), 272-278
DOI 10.1016/j.yexmp.2018.08.008, PubMed 30171833
B7-H3 in Cancer - Beyond Immune Regulation
Trends Cancer, 4 (6), 401-404
DOI 10.1016/j.trecan.2018.03.010, PubMed 29860983
The role of protein tyrosine phosphatases in prostate cancer biology
Biochim Biophys Acta Mol Cell Res, 1866 (1), 102-113
DOI 10.1016/j.bbamcr.2018.06.016, PubMed 30401533
Publications 2017
Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells
Pigment Cell Melanoma Res, 30 (5), 467-476
DOI 10.1111/pcmr.12599, PubMed 28513992
Publications 2016
The Extended Family of Protein Tyrosine Phosphatases
Methods Mol Biol, 1447, 1-23
DOI 10.1007/978-1-4939-3746-2_1, PubMed 27514797
The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases
PLoS One, 11 (12), e0169105
DOI 10.1371/journal.pone.0169105, PubMed 28033421
Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
Oncotarget, 7 (6), 6891-901
DOI 10.18632/oncotarget.6902, PubMed 26771843
Global RT-PCR and RT-qPCR Analysis of the mRNA Expression of the Human PTPome
Methods Mol Biol, 1447, 25-37
DOI 10.1007/978-1-4939-3746-2_2, PubMed 27514798
Publications 2014
Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c
Br J Cancer, 110 (8), 2072-80
DOI 10.1038/bjc.2014.113, PubMed 24577056
Dual-specificity phosphatases as molecular targets for inhibition in human disease
Antioxid Redox Signal, 20 (14), 2251-73
DOI 10.1089/ars.2013.5709, PubMed 24206177
Publications 2013
Protein tyrosine phosphatases as novel targets in breast cancer therapy
Biochim Biophys Acta, 1836 (2), 211-26
DOI 10.1016/j.bbcan.2013.06.001, PubMed 23756181
Publications 2012
Caspase-3 cleavage of DUSP6/MKP3 at the interdomain region generates active MKP3 fragments that regulate ERK1/2 subcellular localization and function
J Mol Biol, 420 (1-2), 128-38
DOI 10.1016/j.jmb.2012.04.004, PubMed 22504224
Publications 2011
Dual-specificity MAP kinase phosphatases as targets of cancer treatment
Anticancer Agents Med Chem, 11 (1), 109-32
DOI 10.2174/187152011794941190, PubMed 21288197
Epidermal growth factor receptor (EGFR)-mediated positive feedback of protein-tyrosine phosphatase epsilon (PTPepsilon) on ERK1/2 and AKT protein pathways is required for survival of human breast cancer cells
J Biol Chem, 287 (5), 3433-44
DOI 10.1074/jbc.M111.293928, PubMed 22117074
Publications 2010
Differential up-regulation of MAP kinase phosphatases MKP3/DUSP6 and DUSP5 by Ets2 and c-Jun converge in the control of the growth arrest versus proliferation response of MCF-7 breast cancer cells to phorbol ester
J Biol Chem, 285 (34), 26417-30
DOI 10.1074/jbc.M110.121830, PubMed 20554528
Studying the regulation of MAP Kinase by MAP Kinase phosphatases in vitro and in cell systems
Methods Mol Biol, 661, 305-21
DOI 10.1007/978-1-60761-795-2_18, PubMed 20811991